Company Filing History:
Years Active: 2014
Title: Jefferey Stephen Boyle: Innovator in Immunotherapy
Introduction
Jefferey Stephen Boyle is a notable inventor based in Pearcedale, Australia. He has made significant contributions to the field of immunotherapy, particularly through his innovative methods involving CD123 antibodies. His work aims to improve treatment options for conditions characterized by CD123-expressing cells.
Latest Patents
Jefferey holds a patent for an immunotherapeutic method involving CD123 (IL-3Rα) antibodies and an immunostimulating complex. This method involves administering to a patient an antibody or antibody fragment that selectively binds to IL-3Rα (CD123), along with an immunostimulating complex that includes saponin, a sterol, and a phospholipid. This patent represents a significant advancement in targeted therapies for specific medical conditions.
Career Highlights
Jefferey is associated with CSL Limited, a leading global biotechnology company. His role at CSL Limited has allowed him to work on groundbreaking research and development projects that focus on innovative therapeutic solutions. His expertise in immunotherapy has positioned him as a key figure in the advancement of medical treatments.
Collaborations
Throughout his career, Jefferey has collaborated with esteemed colleagues, including Debra Pauline Drane and Eugene Maraskovsky. These collaborations have fostered a productive environment for research and innovation, contributing to the success of their projects.
Conclusion
Jefferey Stephen Boyle's contributions to immunotherapy exemplify the impact of innovative thinking in medicine. His patent and work at CSL Limited highlight his commitment to advancing treatment options for patients. His collaborations further enhance the potential for future breakthroughs in the field.